GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Novacyt SA (XPAR:ALNOV) » Definitions » Capital Expenditure

Novacyt (XPAR:ALNOV) Capital Expenditure : €-0.33 Mil (TTM As of Jun. 2023)


View and export this data going back to 2012. Start your Free Trial

What is Novacyt Capital Expenditure?

Cash flow for capital expenditures refers to the funds spent for a company to acquire or upgrade physical assets such as property, industrial buildings or equipment.

Novacyt's cash flow for capital expenditures for the six months ended in Jun. 2023 was €-0.20 Mil. Its cash flow for capital expenditures for the trailing twelve months (TTM) ended in Jun. 2023 was €-0.33 Mil.

Novacyt Capital Expenditure Historical Data

The historical data trend for Novacyt's Capital Expenditure can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Novacyt Capital Expenditure Chart

Novacyt Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Capital Expenditure
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.69 -0.24 -1.31 -4.83 -0.48

Novacyt Semi-Annual Data
Dec13 Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23
Capital Expenditure Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -2.37 -2.43 -0.35 -0.13 -0.20

Novacyt Capital Expenditure Calculation

Cash flow for capital expenditures refers to the funds spent for a company to acquire or upgrade physical assets such as property, industrial buildings or equipment.

Capital Expenditure for the trailing twelve months (TTM) ended in Jun. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was €-0.33 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Novacyt (XPAR:ALNOV) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Novacyt SA (XPAR:ALNOV) » Definitions » Capital Expenditure
Comparable Companies
XPAR:AFME XPAR:ALMKT XPAR:ALTHE XPAR:ALTER XPAR:ALBLU XPAR:ALDMS XPAR:ALEMG XPAR:ALIKO XPAR:ALSGD XPAR:ALIMP ABT SYK MDT BSX SZSE:300760 EW DXCM ZBH STE XAMS:PHIA
Traded in Other Exchanges
NVYTF:USA NCYT:UK NYZ:Germany
Address
13, Avenue Morane Saulnier, Velizy-Villacoublay, FRA, 78140
Website
https://www.novacyt.com
Novacyt SA is engaged in developing and selling diagnostic products for cancer and infectious diseases. The company operates its business through the following business segments. Primerdesign is the designer, manufacturer, and marketer of molecular 'real-time' qPCR testing devices and reagents in the areas of infectious diseases based in Southampton, UK: IT-IS International segment develops PCR devices for the life sciences and food testing industry and Corporate segment.

Novacyt (XPAR:ALNOV) Headlines

No Headlines